Investigating methotrexate dosing and side effects for Burkitt lymphoma in Malawi
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
['FUNDING_CAREER'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-10650283
This study is looking to make treatments better for kids and young adults with Burkitt lymphoma in Sub-Saharan Africa by testing the safest dose of a chemotherapy drug called methotrexate and finding out how it works in the body, while also listening to patients about any side effects they experience.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10650283 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment for Burkitt lymphoma, a common cancer in children and young adults in Sub-Saharan Africa. The project will involve a pilot clinical trial to find the highest safe dose of methotrexate, a key chemotherapy drug. Additionally, researchers will develop a model to understand how the drug behaves in the body and create a tool to assess side effects from the patient's perspective. This comprehensive approach aims to enhance treatment protocols and ultimately improve survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with Burkitt lymphoma in Sub-Saharan Africa.
Not a fit: Patients with other types of cancers or those outside the age range of 0-21 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Burkitt lymphoma.
How similar studies have performed: Previous research has shown promising results in optimizing cancer treatments in resource-limited settings, indicating potential success for this approach.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WESTMORELAND, KATHERINE DOUGLAS — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: WESTMORELAND, KATHERINE DOUGLAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.